β-Secretase as a Therapeutic Target for Alzheimer's Disease
- 1 July 2008
- journal article
- review article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 5 (3), 399-408
- https://doi.org/10.1016/j.nurt.2008.05.007
Abstract
No abstract availableKeywords
This publication has 68 references indexed in Scilit:
- Discovery of Isonicotinamide Derived β-Secretase Inhibitors: In Vivo Reduction of β-AmyloidJournal of Medicinal Chemistry, 2007
- Depletion of GGA3 Stabilizes BACE and Enhances β-Secretase ActivityNeuron, 2007
- GGA1 Is Expressed in the Human Brain and Affects the Generation of Amyloid β-PeptideJournal of Neuroscience, 2006
- Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivoJournal of Neurochemistry, 2006
- Acylguanidines as Small-Molecule β-Secretase InhibitorsJournal of Medicinal Chemistry, 2006
- Design, Synthesis and X-ray Structure of Protein−Ligand Complexes: Important Insight into Selectivity of Memapsin 2 (β-Secretase) InhibitorsJournal of the American Chemical Society, 2006
- Structural Locations and Functional Roles of New Subsites S5, S6, and S7 in Memapsin 2 (β-Secretase),Biochemistry, 2004
- Biochemical and Structural Characterization of the Interaction of Memapsin 2 (β-Secretase) Cytosolic Domain with the VHS Domain of GGA ProteinsBiochemistry, 2003
- Memapsin 2 (β‐secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2FEBS Letters, 2002
- Structure-Based Design: Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase)Journal of Medicinal Chemistry, 2001